v3.7.0.1
Restructuring
3 Months Ended
Mar. 31, 2017
Restructuring and Related Activities [Abstract]  
Restructuring
Restructuring
In the first quarter 2017, we initiated a company-wide restructuring designed to help position the Company for sustainable, long-term growth that we believe will further allow us to fulfill our mission of serving patients and families with rare diseases. For the three months ended March 31, 2017 we recorded $24 of restructuring expenses primarily related to employee separation costs. We currently estimate incurring approximately $5 to $10 of additional restructuring related expenses in 2017. We expect to pay all accrued amounts related to this restructuring within twelve months.
The following table presents a reconciliation of the restructuring reserve recorded within accrued expenses on the Company's condensed consolidated balance sheet for the three months ended March 31, 2017:
 
Employee Separation Costs
 
Contract Termination Costs
 
Other Costs
 
Total
Liability, beginning of period
$

 
$

 
$

 
$

Restructuring expenses
21

 

 
3

 
24

Cash settlements

 

 

 

Adjustments to previous estimates

 

 

 

Asset impairments

 

 
(3
)
 
(3
)
Liability, end of period
$
21

 
$

 
$

 
$
21


The restructuring reserve of $21 is recorded in accrued expenses on the Company's condensed consolidated balance sheet as of March 31, 2017.